Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 3,900 trials

Severe Pneumonia: Testing Trimodulin

We are studying whether trimodulin can improve survival in hospitalized adults with severe pneumonia compared to a placebo. The trial also looks at the safety and effects of the treatment.

Community Acquired PneumoniaConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Atrial Fibrillation: Semaglutide for Weight Control

We are studying whether a weekly injection of semaglutide helps people with obesity and atrial fibrillation achieve a normal heart rhythm. The trial also looks at how weight loss affects symptoms and quality of life.

ObesityAtrial Fibrillation1-2 yearsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCardiologyEndocrinologyInternal Medicine

Myeloid Diseases: DFV890 Treatment Study

We are investigating the safety and effectiveness of DFV890 in adults with myeloid diseases. This study aims to understand how well this treatment works and how it is tolerated.

Myeloid Dysplasia>2 yearsSafety phase (I)HematologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Cognitive Deficits in Multiple Sclerosis: MODAFIMS Study

We are studying the effects of modafinil on cognitive deficits in people with Multiple Sclerosis. The trial aims to identify brain features that may predict treatment response and assess changes in cognitive function and quality of life.

Multiple Sclerosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

Skin Candidiasis: Mecloderm® Ointment Study

We are comparing a new ointment with clotrimazole and betamethasone to an existing treatment and a placebo for patients with moderate to severe skin infections caused by yeast. The study aims to assess how well these treatments work and their safety.

Skin and Nail Candidiasis≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesDermatologyInfectious Diseases

Heart Attack Recovery: Milvexian Study

We are testing a new oral medication, milvexian, to see if it helps reduce the risk of further heart problems in patients after a heart attack. This study compares milvexian to a placebo alongside standard treatment.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Dexamethasone for Moderate to Severe Depression

We are studying whether adding dexamethasone to standard depression treatment can improve symptoms for those with moderate to severe depression. This trial aims to assess its safety and effectiveness.

Depression6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Breast Cancer: Elacestrant vs. Standard Therapy

We are studying whether elacestrant can help women with ER+/HER2- breast cancer who have signs of relapse delay cancer spread compared to standard treatments. The trial also looks at safety and how patients feel about the treatment.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

ALK-Positive Anaplastic Large Cell Lymphoma: Vinblastine Treatment

We are studying whether Vinblastine can effectively treat children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma. The goal is to see if it can cure at least 75% of these patients.

ALK-positive Anaplastic Large Cell Lymphoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Atypical Teratoid/Rhabdoid Tumors: High-Dose Chemotherapy vs. Radiotherapy

We are studying whether high-dose chemotherapy is as effective as radiotherapy for young children with ATRT. This trial aims to improve treatment options and understand the long-term effects on health and quality of life.

Atypical Teratoid/Rhabdoid Tumors (ATRT)>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Atopic Dermatitis: Lebrikizumab for Kids

We are studying a new treatment for children and teens with moderate-to-severe atopic dermatitis. The goal is to see if it works better than a placebo when used alongside standard treatments.

Atopic Dermatitis (Eczema)3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesDermatology

Advanced Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab Study

We are studying whether a combination of Fianlimab and Cemiplimab is more effective than Cemiplimab alone for adults with advanced non-small cell lung cancer. This trial focuses on patients whose tumors express PD-L1 at high levels.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPartially RemoteOncology

Hypertension in Chronic Kidney Disease: Diuretic Treatment Study

We are investigating if a new diuretic-based treatment helps people with moderate to severe chronic kidney disease and uncontrolled hypertension. The goal is to see if it can reduce serious health issues like kidney failure and heart problems.

Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyNephrology

HER2-positive Breast Cancer: Trastuzumab Deruxtecan Study

We are comparing a new treatment with standard therapy for patients with HER2-positive breast cancer. The goal is to see which approach leads to better outcomes and to understand the effects on quality of life.

HER2 Positive Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Triple-Negative Breast Cancer: PLX038 Treatment Study

We are studying the effects of PLX038 in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to see how well it works and to understand its safety and tolerability.

Advanced Triple-Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: Sacituzumab Govitecan Study

We are exploring a new medication for patients with advanced or metastatic solid tumors who also have moderate liver impairment. The goal is to find a safe starting dose for this treatment.

Solid Tumors≤3 monthsSafety phase (I)HepatologyOncology